Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells
Background
Chimeric antigen receptor (CAR)-T cells face many obstacles in solid tumor therapy, including heterogeneous antigen expression and inefficient T cell persistence. Guanylyl cyclase C (GUCY2C) has been identified as a suitable tumor antigen f…